… may represent a significant clinical advantage. Among NOACs, edoxaban is the last to reach
… agents, we will focus this review on drug interactions, considering edoxaban, a NOAC with …

… Asian population were thinner than the Western populations in general, whether the
impact of BMI on edoxaban exposure is clinically significant remained unclear from our data. …

… practice and to clarify which FXI inhibitor may be most suited for each clinical indication.
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, …

… review the basic physiology of hemostasis, pharmacology of … medications are used in the
clinical setting. The mechanism of … edoxaban remains to be the most sensitive test for edoxaban …

… VKAs, but not with apixaban and edoxaban vs. VKAs [4]. Many unmet needs remain in the
field of … The aim of this review is to summarize pharmacology and current clinical evidence on …

… In conclusion, this validated UHPLC–MS/MS method allows an accurate quantification of
edoxaban and its active-metabolite, edoxaban-M4, in human plasma according to the …

… The PK and PD profiles of edoxaban were found to … edoxaban is feasible at the current dose
regimen. These findings may encourage enhanced confidence in the clinical pharmacology …

… of no differences in patient outcomes after edoxaban versus warfarin, apixaban, … the clinical
questions about the comparative effectiveness and safety of the oral anticoagulant edoxaban …

… This review focuses on potential pleiotropic effects of FXa inhibition with edoxaban seen
in … As common findings from these experiments, edoxaban was able to attenuate FXa- and …

… Results of clinical studies clearly show that inhibitors of factor Xa, rivaroxaban, apixaban,
and edoxaban exert their pharmacological effect in a concentration-dependent manner [15,16,…